Molecular Partners

MOLNNasdaq Switzerland Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$120.598 M

$3.22 -1.98%

Close of 6 Nov 2026

As of 6 Nov 2026, Molecular Partners (MOLN) has a market capitalization of $120.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

40,374,641

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#102Protara TherapeuticsTARA$125.9M
#103Compass TherapeuticsCMPX$125.1M
#104Molecular PartnersMOLN$120.6M
#105Coherus OncologyCHRS$115.9M
#106enGene TherapeuticsENGN$113.6M

What if Molecular Partners were worth as much as…

Open the what-if tool →

Gold $28.2T

$752,759.22

Per share 234,140× higher

Bitcoin $1.53T

$40,730.49

Per share 12,669× higher

Apple $5.02T

$133,714.40

Per share 41,591× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Molecular Partners are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.